Absorbing Debate: Boston Sci, Abbott Differ On Whether The Future Of Stents Is To Disappear
Competing visions of the future of percutaneous coronary interventions were on display at TCT year, with Boston Scientific pushing its Synergy bioabsorbable polymer-coated, drug-eluting metal stent platform as the better long-term option to fully-resorbable scaffolds of the type Abbott is first out of the gate with.
You may also be interested in...
Boston Scientific and inVentive Health recently sponsored a webinar with four internationally well-known experts on coronary stent technology to discuss the pros and cons of new bioabsorbable polymer stent technologies – both the fully resorbable stents and metal drug-eluting stents with a bioresorbable polymer. Here's a summary of the discussion. Medtech Insight is also providing a complete transcript of the event.
The US Market for interventional cardiology products, which includes diagnostic and therapeutic products, is anticipated to expand from an estimated $3.3 billion in 2015 to roughly $3.6 billion in total product sales by the year 2020. One bright spot in this otherwise lackluster market is the interventional diagnostic products segment, which is projected to grow at CAGR of 4.7% and reach almost $1 billion by 2020, according to a report by Medtech Insight.
While a panel of FDA experts almost unanimously voted to recommend Abbott's fully bioabsorbable Absorb scaffold, analysts say the stent is unlikely to take significant market share, at least in its current form.